Follow The Filings

ZNTL Zentalis Pharmaceuticals Inc.

Health Care, filed as ZENTALIS PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.6%
  • $6.9M

Who owns this now

Largest portfolio weights among holders, up to 0.6% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman 0.62%

Who owns ZNTL

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.62% Hold 1,412,656 $6.9M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ZNTL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ZNTL insider trades
  • $22.9M bought by 1 insider
  • $10M sold by 1 insider outside a trading plan
  • $18K sold by 1 insider under 10b5-1 plans
  1. Walters Group 10% owner, +2 joint filers
    Buy
    $15.2M 4,335,000 shares at $3.50 +32% to stake
    Traded Aug 14 Filed Aug 19
    ↗
  2. Vincent Vultaggio PAO and PFO
    Planned sale
    $17K 6,894 shares at $2.42 4.5% of stake
    Traded Feb 10 Filed Feb 10
    ↗
  3. Vincent Vultaggio PAO and PFO
    Planned sale
    $1,398 556 shares at $2.52 0.3% of stake
    Traded Feb 3 Filed Feb 4
    ↗
  4. Walters Group 10% owner, +2 joint filers
    Buy
    $7.8M 6,459,973 shares at $1.20 +92% to stake
    Traded Dec 31, 2025 Filed Jan 8
    ↗
  5. Matrix Capital Management Company, LP 10% owner, +1 joint filer
    Sale
    $10M 7,500,000 shares at $1.33 54% of stake
    Traded Dec 15, 2025 Filed Dec 15, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants and 7 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 2.02,7.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01 Filing Doc
8-K 2.02,7.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01 Filing Doc
8-K 7.01,8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,8.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $67.42M $0M
Net income -$292.19M -$165.84M -$137.06M
Net margin * — -246.0% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $496.72M $386.07M $253.19M
Total non-current assets * $54.97M $44.27M $35.78M
Total assets $551.69M $430.34M $288.97M
Total current liabilities $69.37M $52.72M $36.56M
Total non-current liabilities * $44.93M $40.43M $36.2M
Total equity $437.28M $337.19M $216.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$207.82M -$170.86M -$125.25M
Cash from investing -$44.46M $176.56M $131.62M
Cash from financing $237.3M $0.108M -$4.28M
Net change in cash -$14.98M $5.81M $2.09M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.